GLP-3RT 12MG is a GGG tri-agonist that targets GLP-1 and GIP receptors, akin to standard GLP-1 agonists, but also uniquely activates the glucagon receptor. This extra receptor interaction enhances glucagon production, thereby increasing basal metabolism. Its actions on GLP-1 and GIP receptors promote delayed gastric emptying and appetite control, offering a comprehensive approach to obesity research distinct from older GLP-1 agonists.
Clinical Data:
GLP-3RT: Triple–Hormone-Receptor Agonist for Obesity — A Phase 2 Trial
GLP-3RT: A Study (LY3437943) in Participants With Obesity and Cardiovascular Disease (TRIUMPH-3)
GLP-3RT: Triple-Hormone-Receptor Agonist Study for Obesity – A Phase 2 Trial
GLP-3RT 12MG is a GGG tri-agonist that targets GLP-1 and GIP receptors, akin to standard GLP-1 agonists, but also uniquely activates the glucagon receptor. This extra receptor interaction enhances glucagon production, thereby increasing basal metabolism. Its actions on GLP-1 and GIP receptors promote delayed gastric emptying and appetite control, offering a comprehensive approach to obesity research distinct from older GLP-1 agonists.
Clinical Data:
GLP-3RT: Triple–Hormone-Receptor Agonist for Obesity — A Phase 2 Trial
GLP-3RT: A Study (LY3437943) in Participants With Obesity and Cardiovascular Disease (TRIUMPH-3)
GLP-3RT: Triple-Hormone-Receptor Agonist Study for Obesity – A Phase 2 Trial